CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Angiex Inc., a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, today announced the completion of ...
Proceeds support ongoing all-comers Phase 1 trial of TM4SF1-directed Nuclear-Delivered ADC AGX101 CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Angiex Inc., a developer of Nuclear-Delivered ...
A domestic research team subdivided obesity in Koreans into general and abdominal types and identified the correlation between genes and eating habits. This study is the first in Korea to analyze the ...
A RECENT study has uncovered promising insights into histologic variant (HV) bladder cancers, rare and aggressive forms found in up to 25% of all bladder tumours. Unlike typical urothelial carcinoma ...
Histologic variant (HV) subtypes of bladder cancer are clinically aggressive tumors that are more resistant to standard therapy compared to conventional urothelial carcinoma (UC). Little is known ...
Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies. Scientists at UC San Francisco have found a way to identify and possibly treat ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies. Scientists at UC San Francisco have found a way to identify and possibly treat ...
AGX101: A TM4SF1-directed tubulin inhibitor conjugate in ongoing first-in-human trial including GI cancers. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results